Comments
Lupin on Wednesday said it has received nod from the US Food and Drug Administration to market its Atovaquone oral suspension in the strength of 750 mg/5 mL. The product is a generic version of GlaxoSmithKline LLC’s Mepron oral suspension in the same strength, it added.
As per IQVIA MAT June 2018 data, Atovaquone oral suspension, 750 mg/5 mL had annual sales of around $117.4 million in the US, Lupin said. Shareholders will monitor the development.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.